Zejula is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor developed to treat advanced ovarian, fallopian tube, or primary peritoneal cancer patients, who have been treated with three
The acquisition is centered on a pre-clinical lead asset that complements Zealand’s focus on developing next-generation peptide therapeutics for gastrointestinal diseases. The lead asset, ET3764, is being developed
Moderna has designed mRNA-3927 to instruct the body to restore the missing or dysfunctional proteins, which cause PA. PA is a rare, life-threatening and inherited a metabolic disorder
This is the first pediatric approval for ULTOMIRIS. Atypical HUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to
The Company expects to report top-line results from CONTESSA in the third quarter of 2020. Tesetaxel is an investigational, orally administered chemotherapy agent that belongs to a class
The FDA approval was based on data from the DECLARE-TIMI 58 CV outcomes trial (CVOT). It is claimed to be the largest sodium-glucose cotransporter 2 (SGLT2) inhibitor CVOT
Under the deal, Bavarian Nordic will purchase the manufacturing and global rights related to travel vaccines Rabipur/RabAvert to prevent rabies and Encepur to prevent TBE. The deal includes
The Prescription Drug User Fee Act (PDUFA) date for trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC) and potential new medicine for the treatment of HER2-positive metastatic breast
The FDA has approved the company’s supplemental new drug application (sNDA) for Xofluza to treat acute, uncomplicated influenza, or flu, in people 12 years of age and older
The center of excellence specializes in injectable pharmaceutical capabilities including flexible manufacturing solutions for liquid and lyophilized products. The facility, located at 627 Davis Drive in Morrisville and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.